KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Current Deferred Revenue (2016 - 2023)

Palvella Therapeutics has reported Current Deferred Revenue over the past 8 years, most recently at $20.8 million for Q4 2022.

  • Quarterly Current Deferred Revenue fell 17.09% to $20.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $20.8 million through Dec 2022, down 17.09% year-over-year, with the annual reading at $20.8 million for FY2022, 17.09% down from the prior year.
  • Current Deferred Revenue was $20.8 million for Q4 2022 at Palvella Therapeutics, up from $700000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $46.3 million in Q1 2018 and troughed at $700000.0 in Q3 2022.
  • The 5-year median for Current Deferred Revenue is $24.0 million (2021), against an average of $22.7 million.
  • Year-over-year, Current Deferred Revenue surged 794.84% in 2018 and then tumbled 97.35% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $35.6 million in 2018, then crashed by 68.39% to $11.3 million in 2019, then rose by 12.18% to $12.6 million in 2020, then skyrocketed by 98.91% to $25.1 million in 2021, then dropped by 17.09% to $20.8 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Current Deferred Revenue are $20.8 million (Q4 2022), $700000.0 (Q3 2022), and $22.9 million (Q2 2022).